Akero Therapeutics, Inc.
CIK 0001744659
Revenue (TTM)
—
Q3 Nov 2025
Net Income (TTM)
−$295.5M
−66.1% YoY
Q3 Nov 2025
EPS Diluted (TTM)
−$3.80
−29.8% YoY
Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
—
Q3 Nov 2025
Net Margin
—
Q3 Nov 2025
Free Cash Flow (TTM)
−$150.46M
Q3 Nov 2025
Cash
$176.03M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
82.32M sh
Q3 Nov 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.